DefinitionThis section has been translated automatically.
Cytokine. Pegylated granulocyte colony stimulating factor produced by recombinant DNA technology (see pegylation below).
Half-lifeThis section has been translated automatically.
In comparison with Filgrastim, pegfilgrastim has a kinetics that is about 10 times slower (pegylation of Filgrastim molecules) and the elimination half-life of pegfilgrastim is therefore about ten times longer than that of Filgrastim (about 30 versus about 3 hours). The time to reach the maximum plasma concentration is about nine times longer (about 72 hours versus about 8 hours).
You might also be interested in
Pharmacodynamics (Effect)This section has been translated automatically.
Reduction of the duration of neutropenia and the frequency of neutropenic fever after chemotherapy. Within 24 hours the number of neutrophilic granulocytes in peripheral blood increases, monocytes and lymphocytes hardly react.
IndicationThis section has been translated automatically.
Shortening the duration of neutropenia and reducing neutropenic fever in patients treated with myelosuppressive chemotherapy (e.g. with doxorubicin) due to a non-myeloic underlying disease. Long-term therapy of severe congenital or idiopathic neutropenia. No influence on chemotherapy-induced thrombopenia and anaemia.
Notice!
Caution with malignant and premalignant diseases of myeloid origin. Use only under the supervision of oncologically experienced doctors!Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated.
Dosage and method of useThis section has been translated automatically.
Per chemotherapy cycle: 6 mg s.c. approximately 24 hours after cytotoxic chemotherapy application.
Undesirable effectsThis section has been translated automatically.
Passengers with bone pain, pain at the injection site.
ContraindicationThis section has been translated automatically.
Pregnancy, lactation, underlying myeloid disease, restricted bone marrow function of unclear etiology, liver and kidney failure, hypersensitivity to proteins derived from E. coli.
PreparationsThis section has been translated automatically.
Neulasta
Prof. Dr. med. Peter Altmeyer